Biofrontera (BFRI) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues reached $8.6 million, up 9% year-over-year, driven by higher Ameluz sales and the launch of the RhodoLED XL lamp.

• Net loss narrowed to $4.2 million from $10.4 million in Q1 2024, reflecting improved gross profit, lower operating expenses, and reduced non-cash warrant liability changes.

• Maintained cost discipline, reducing both cost of revenue and operating expenses compared to Q1 2024.

• Achieved key clinical milestones, including final patient enrollment in Ameluz Phase 3 trial for actinic keratoses, completed 1-year follow-up in sBCC study, and advanced studies for acne.

• Received patent approval for revised Ameluz formulation, extending protection to December 2043.

Financial highlights

• Revenue increased by $0.7 million (8.7%) year-over-year to $8.6 million in Q1 2025, mainly from Ameluz price increases and RhodoLED XL Lamp sales.

• Operating expenses decreased to $13.1 million from $13.4 million year-over-year.

• Cost of revenues, related party, dropped by $0.9 million (22.1%) to $3.1 million due to a revised Ameluz license and supply agreement.

• Adjusted EBITDA improved to $(4.4) million from $(4.6) million, with margin improving to -51.0% from -57.9%.

• Gross profit increased by $1.5 million year-over-year, offset by a $1.2 million rise in R&D expenses.

Outlook and guidance

• Management anticipates continued revenue growth in 2025, leveraging expanded clinical indications, new product launches, and sales force effectiveness.

• Anticipate FDA submissions for label expansion and new indications in the second half of 2025.

• Ongoing focus on cost control and operational efficiency to reach break-even.

• Management plans to secure additional capital through financing or asset sales, with no assurance of success.